Finding a Safe Dose of a New Drug for Some Types of Solid Tumors
LMB-100 is a lab-created protein that targets mesothelin. It is being tested against pancreatic cancer and other solid tumors in a clinical trial.
Tough Tortoise of a Drug Beating Metastatic Pancreatic Cancer
Rexahn Pharmaceuticals is testing RX-3117, a slow-releasing drug similar to gemcitabine, in a clinical trial for metastatic pancreatic cancer patients.
Radiotherapy Implant plus Standard Chemotherapy
The OncoSil radiotherapy implant device is being tested on pancreatic cancer in a clinical trial that combines it with standard chemotherapy.
A Combination of Neoadjuvant Chemotherapy and Radiation Shows Promise
Dr. Alok Khorana discusses the results of clinical trials of neoadjuvant chemotherapy and radiation to make surgery more effective.
A New Combination Chemotherapy Before Surgery
A new clinical trial adds vitamin D to standard of care chemotherapy before surgery, to make pancreatic cancer tumors more removable.
Testing the Effectiveness of Immunotherapy Added to a New Drug Combination
Researchers are testing a drug combination that adds immunotherapy to standard drugs used to treat pancreatic cancer and an antimalarial drug.
Testing Immunotherapy for Safety Before and After Pancreatic Cancer Removal
Researchers are testing a new monoclonal antibody to see if it helps patients with pancreatic tumors that can be surgically removed.
Collaborative Multi-Center Immunotherapy Trial Targets CD40 and PD-1
Dr. Mark O’Hara outlines a collaborative clinical trial of two immunotherapy agents–a checkpoint inhibitor and a monoclonal antibody–plus standard chemotherapy.
Helping Some Types of Chemotherapy Penetrate Pancreatic Tumors
A clinical trial looks at the effectiveness of PEGPH20 in helping chemotherapy penetrate the stroma of pancreatic tumors, to make them removable.
New Cancer Stem Cell Pathway Drug May Change Standard of Care
Dr. Tanios Bekii-Saab is testing a new drug that works on pancreatic cancer stem cells to make chemotherapy more effective.
